Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA private prescription for Mounjaro in the UK is priced per four-week pen, and the cost varies by dose and provider — typically ranging from around £149 to £375 per month across the market since Eli Lilly raised its UK list price in September 2025. That price should always include a clinical assessment; Mounjaro is a prescription-only medicine, and no legitimate provider can supply it without one. What changes between services is what else that figure covers — or doesn't.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Eli Lilly's decision to restructure Mounjaro's UK list price from 1 September 2025 is the main reason you'll see such wide figures quoted online. Before that change, the highest-dose pen had a list price of around £122; afterwards, that same pen rose to around £330. Private providers set their own retail prices on top, which is why published monthly costs now span from the low £100s to well over £300, depending on the dose you're on and who you're buying from. As reported widely in August 2025, the adjustment was substantial and felt immediately across the private market.
The dose matters more than most people realise when comparing prices. Treatment starts at 2.5mg (a tolerability dose designed to let your system adjust) and most people titrate upward over several months, reaching doses like 10mg or 15mg where the SURMOUNT-1 trial, published in the New England Journal of Medicine, recorded average body-weight reductions of around 20–21%. The monthly cost at 15mg is meaningfully higher than at 5mg, so a single headline figure tells you very little without knowing which dose it refers to. You can find a fuller breakdown of how the UK private cost varies by dose on our Mounjaro private cost in the UK page.
One common misconception worth setting aside: Mounjaro is not routinely available on the NHS for most people yet. The NHS rollout through NICE's technology appraisal TA1026 is phased and criteria are strict, so most people accessing it right now are doing so through private prescription, and our page on how much Mounjaro costs on prescription explains what that typically means for your wallet. That's the market context for everything that follows.
A single monthly figure can look clean and competitive until you read the small print. Some providers charge a separate consultation fee (typically £20–£50) before any medicine is prescribed. Others issue a paper prescription that you then take to a high-street pharmacy, adding a dispensing fee and sometimes a delay. Delivery may be charged on top, and aftercare (follow-up support, dose-review conversations, advice if you have a reaction) can be billed as an add-on or simply not offered at all.
There is also the question of clinical depth. A legitimate Mounjaro prescription requires a real assessment of your medical history, current medicines, BMI and any relevant conditions. A service that charges very little for this step, or appears to skip it, should prompt questions rather than confidence. Our guide to Mounjaro private pricing covers the typical line-items worth checking before you commit to any provider.
At nume, a single transparent price covers the consultation, the prescription, the medicine dispensed from our own pharmacy, and free next-working-day delivery. There are no extras to find. We're not the cheapest option in the market, that's a deliberate choice, not an oversight. The trade-off is a GPhC-registered pharmacy, a named prescriber reading your consultation the same day (not software routing it overnight), and clinical re-review before every repeat order. If you'd prefer to spread costs more predictably, our page on Mounjaro monthly subscription options sets out how that structure works.
For a Prescription-Only Medicine like Mounjaro, the question isn't which provider quotes the lowest number. It's whether the supply chain is licensed, the clinical assessment is genuine, and the pharmacy is registered and accountable. The MHRA has warned publicly about counterfeit weight-loss pens sold online, some fake pens have been found to contain insulin, and in October 2025 the first UK illicit manufacturing site producing counterfeit tirzepatide pens was raided. Sellers offering Mounjaro without a clinical assessment, or at prices far below market rate, are a red flag, and our page on finding the cheapest Mounjaro in the UK without a subscription explains how to tell a legitimate low-cost option from one that should give you pause. You can verify any online pharmacy on the GPhC register, that's the quickest check.
For context on what the full monthly cost looks like in practice across different doses and what's included, see our Mounjaro price page. If you'd like to understand what the oral form of tirzepatide is likely to cost when it becomes more widely available, our page on oral tirzepatide cost covers what's known so far. When you're ready to find out whether you're clinically suitable, a free consultation with our prescribers is the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.